Kornimate/medical-research-clean huggingface dataset:
catestatin and hypertension in pregnancy

Conditions: Pre-Eclampsia; Eclampsia; Hypertension, Pregnancy-Induced; Hypertension in Pregnancy

Summary: catestatin is a kind of protein involved with cardiovascular disease. accumulated evidence shows that catestatin may be a predictor of primary hypertension, but whether it plays the same role in pregnant hypertensive disorders needs to be determined. by measuring the plasma level of catestatin, main biochemical marks and ucg in healthy pregnancy and pregnancy with hypertension, the research may contribute to this problem.


Eligibility criteria:
inclusion criteria: * healthy pregnancy women * pregnancy women with hypertension 1. despite the pregnant gestational age , systolic blood pressure ≥140 mm hg or a diastolic blood pressure of ≥90 mm hg measured three times more than 24 hours apart 2. pregnant gestational age \> 20 weeks, systolic blood pressure ≥140 mm hg or a diastolic blood pressure of ≥90 mm hg measured twice more than 4 hours apart exclusion criteria: * lack of blood sample at the specified enrollment period * women who refuse the study * other illness which needs medications interfering with blood pressure (eg: asthma requiring systemic steroids) * known coronary artery disease or heart failure * serious medical illness (eg: renal insufficiency, congestive heart disease, chronic respiratory insufficiency, uncontrolled infection). * multiple endocrine neoplasia or cushing's syndrome or mixed tumours or pheochromocytoma or medullary thyroid carcinoma. * previous history of malignant tumour, with the exception of carcinoma in situ of the uterine cervix or non-melanoma skin cancer * renal insufficiency

Keywords: hypertension pregnancy catestatin
ucmsc transplantation in the treatment of cartilage damage

Conditions: Cartilage Damage; Degenerative Osteoarthritis

Summary: the purpose of this study is to investigate the efficacy and safety of transplantation of umbilical cord mesenchymal stem cells（ucmscs） in patient with knee cartilage damage.

human cartilage only has limited regenerative potential. transplantation of umbilical cord mesenchymal stem cells (ucmscs) is a promising strategy given the high proliferative capacity of mscs and their potential to differentiate into cartilage-producing cells - chondrocytes. the acquisition of ucmscs does not require invasive surgical intervention or cartilage extraction from other sites as required by other cell-based strategies. the investigators inject allogeneic human mesenchymal stem cells to the cartilage lesions in patients via intra-articular injection method, and to investigate the efficacy and safety。

Eligibility criteria:
inclusion criteria: * patients whose lesion (single joint) should be in the range of 2 cm\^2-8 cm\^2. * patients with pain in affected joint of 60 mm- 100 mm vas (visual analogue scale) * patients with articular swelling, tenderness and active range of motion of grade 2 or below * patients with knee joint cartilage defect or injury of icrs (international cartilage repair society) grade 4 confirmed by arthroscopy (at screening, patients diagnosed as such with an mri may be included) * patients who needs invasive interventions of arthroplasty due to no response from existing pain medication * patients voluntarily agreed to participate in the study and signed informed consent exclusion criteria: * patients with autoimmune diseases or medical history * patients with infections requiring injection of antibiotics * patients with severe internal diseases * patients who are currently pregnant or lactation * patients who had participated in any other clinical trials within the past four weeks * patients who had been administered with immunosuppressants within the past four weeks * patients whom the principal investigator considers inappropriate for the clinical trial due to any other reasons than those listed above
central compartment neck dissection with thyroidectomy

Conditions: Indeterminate Thyroid Nodules

Summary: when a patient presents with a thyroid mass, part of the work-up may include a fine needle aspiration biopsy (fnab). the results of the biopsy then help plan treatment. if the results are benign, the management will typically be to follow the nodule. if the results demonstrate or are suspicious for cancer, such as papillary thyroid carcinoma (ptc), the treatment is a total thyroidectomy (total thyroid removal). the latest american thyroid association guidelines for ptc (2009) suggest that in many instances a central lymph node dissection (clnd) should be performed in conjunction with the total thyroidectomy. this procedure consists of removing the lymphatic (glandular) tissues surrounding the thyroid itself, as this tissue may have a propensity for cancer spread. the procedure's necessity has met much controversy in the last decade, but is becoming more of a standard in thyroid cancer surgery. when a thyroid nodule fnab is reported as indeterminate, the treatment strategy is less clear cut. while a diagnostic hemi-thyroidectomy or therapeutic total thyroidectomy may be in order, the inclusion of clnd is not clearly defined. in many centers a clnd will be omitted with surgical management for an "indeterminate" lesion, while in others, it is standard protocol. the argument of performing clnd is largely based on the tenet that it adds little surgical time, cost or risks to the patient. because the evidence of the prognostic role of lymph node metastases is limited many would argue that the risk of not performing clnd is greater than performing clnd. furthermore, in the event of finding cancer on final pathology, and thus, having to re-operate in the thyroid/central compartment bed, post-operative complications may increase. opponents of clnd argue that there is a paucity of strong evidence supporting clnd in the improvement of oncologic outcomes and can potentially increase post-operative low calcium levels or vocal nerve damage however, these recommendations are based on retrospective level iii evidence. thus the debate continues: is clnd justified as an adjunct to hemi-or total thyroidectomy in indeterminate thyroid pathology? the hypothesis is: clnd in hem- or total thyroidectomy for "indeterminate" thyroid nodules will not increase post-operative complications.


Eligibility criteria:
inclusion criteria: * indeterminate or benign pathology on fine needle aspirate biopsy * scheduled to undergo total or hemi-thyroidectomy * \> 18 years old exclusion criteria: * previous thyroid surgery * previous neck surgery in field of thyroidectomy * previous neck irradiation * pre-operative hypocalcemia or hypoparathyroidism * biopsy suggestive of thyroid cancer * neck nodes suspicious for or with known cancer * pre-operative vocal cord dysfunction

Keywords: indeterminate thyroid nodule fine needle aspirate biopsy thyroidectomy central lymph node dissection
aquatic versus land based exercise on lymphedema post mastectomy

Conditions: Breast Cancer

Summary: fifty eligible breast cancer survivors (median, 10 yrs after surgery) with arm lymph-edema (median, 21% inter limb difference) were included and randomized into the intervention(group a, n = 25) or control ( group b, n = 25). intervention group received 60 minutes aquatic-based exercise in the form of warm-up for 10 mins, then strengthening exercise for 40 minutes, followed by 10 min cooling down in the form of stretching and mobility exercise, three times a week for 8 weeks, plus land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise. the control group received 60 minutes of land base exercise, three times a week, for 8 weeks. arm volume, shoulder flexion, abduction range of motion and pain using a visual analogue scale were assessed at baseline and after 8 weeks of treatment.

group a: 25 female patients there aged ranged from 37 to 67 years old with bcrl, in group-a had been dealt with water-based exercise was conducted at a hydrotherapy pool for the eden health care, cairo, the pool measures 8 × 15 m and ranges from 1 to 1.8 m in depth with access via steps. interventions were conducted predominately in the deeper section of the pool so participants immerse their neck in water. control group, group b: 25 female patients there aged ranged from 37 to 67 years old with bcrl, in control group had been dealt land-based exercise program: supervised program consisted of 60-min sessions, three times a week, over 8 weeks. the exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. then the last 10 minutes for cooling down for stretching exercise for the arm muscles .

Eligibility criteria:
inclusion criteria: * breast cancer with unilateral axillary lymph node excision. * mild-moderate degreed lymphedema (stage i and ii) . * lymphedema with a duration of at least 1 year . exclusion criteria: * recurrence of cancer. * ongoing active oncological treatment. * functional disorders hindering participation in exercise programs. * open wound at any area of the body.

Keywords: aquatic exercise- land based exercise lymphedema
an intervention to improve management of dyslipidemia in primary care

Conditions: Cardiovascular Disease; Dyslipidemia; Diabetes Melletus; Obesity

Summary: to assess the effectiveness of a clinical audit and physician based intervention in improving the management of dyslipidemia at health centres in the southeast health region of jamaica


Eligibility criteria:
inclusion criteria: * attended the clinic for at least 18 months * is diagnosed with any of hypertension, diabetes, dyslipidemia, stroke, coronary heart disease (including angina, myocardial infarction), congestive cardiac failure or peripheral arterial disease, were eligible to be included in the audit exclusion criteria: * acutely ill or was diagnosed with established kidney disease
a study to evaluate the safety and efficacy of plm60 in advanced hcc

Conditions: Advanced Hepatocellular Carcinoma

Summary: this is a dose escalation study based on 3+3 design with the aim to establish mtd and provide rp2d. plm60 is to administered by multi-cycle intravenous infusion.


Eligibility criteria:
inclusion criteria: * signed informed consent from the patient； * ecog performance status of 0 or 1; * histologically/cytologically confirmed diagnosis of advanced hcc; * adequate washout period for previous anti-tumor therapy; * measurable disease according to recist v1.1; * life expectancy ≥ 12 weeks; * adequate organ function; * child-pugh grade a or partial grade b; bclc stage b or c;v exclusion criteria: * prior treatment with mitoxantrone or liposome-entrapped mitoxantrone, or other anthracyclines, with the total cumulative dose of \> 360 mg/m2 ; * any drug-related adverse event derived from any previous anti-tumor treatment, excluding alopecia, pigmentation, or other toxicity with little safety risk for subjects, that has not recovered to grade1 or less; * active central nervous system (cns) metastases (brain or leptomeningeal metastases, etc.); * any history of other malignancy within 5 years; * untreated hepatitis infection; * hiv positive; * history of liver transplantation, severe cirrhosis, hepatic encephalopathy; * inadequate cardiac function; * pregnant or lactating women.
pregabalin open-label extension trial in patients with partial seizures

Conditions: Epilepsies, Partial; Epilepsy, Complex Partial

Summary: the primary purpose of the protocol is to evaluate the long-term safety of pregabalin in patients with partial seizures.


Eligibility criteria:
inclusion criteria: * patients must have met the inclusion criteria for study 1008-157, have received double-blind study medication, and wish to receive open-label pregabalin * have the diagnosis of epilepsy with partial seizures and have a minimum of 4 partial seizures during the 6 weeks prior to screening * be currently taking 1 to 3 aeds. exclusion criteria: * have a treatable cause of seizures * experienced a serious adverse event during study 1008-157 which was determined to be possibly related to study medication
self-management for youth and families living with scd - smyls

Conditions: Sickle Cell Disease

Summary: the purpose of this proposal is to integrate family-centered self-management strategies with mobile health (mhealth) technology to improve reach, self-management behaviors, and child and caregiver physical and psychosocial symptoms and quality of life. specifically, the investigators propose to conduct feasibility testing of smyls, which has been adapted based on user feedback in the first phase of this study. first the investigators will work with the medical university of south carolina (musc) pediatric sickle cell clinic to identify and recruit families with children with sickle cell disease (scd) in the community, statewide. next, the investigators will test the feasibility of the intervention with 30 dyads of children ages 8 - 17 with sickle cell disease and their parent or primary caregiver, (n=60)


Eligibility criteria:
inclusion criteria: * children ages 8 - 17 years and parent or primary caregiver 18 years or older * child with sickle cell disease, as reported by clinician at musc pediatric sickle cell clinic exclusion criteria: * parent/caregiver or child with cognitive disability or delay that precludes ability to participate * lack of wi-fi access
study of robot-assisted arm therapy for acute stroke patients

Conditions: Acute Stroke; Paresis

Summary: the purpose of this study is to compare standard occupational therapy to a combination of conventional (standard) and robotic therapy. the reo go device will provide robotic therapy that gives therapists a tool that could make stroke treatment faster and better by helping patients practice more accurate arm movements with help from the device.

hypotheses * motor function will be significantly greater for the patients in the robotic training group as measured by standard clinical evaluations. * functional independence gains will be similar for both groups because the robotic therapy is not task-specific for activities of daily living (adl). * robotic training will reduce pain and spasticity more effectively than conventional therapy alone, due to increased number of movements performed during the robotic training. * muscle activation patterns for patients receiving robotic training will show decreased agonist/antagonist co-contraction and less erratic muscle activation. * robotic training patients will demonstrate significantly greater rom, movement accuracy and higher movement speed during exercises performed as part of robotic training. for robotic exercises performed only as part of the robotic assessment, these improvements will be significantly less than those for practiced movements.

Eligibility criteria:
inclusion criteria right hemisphere, unilateral ischemic stroke with onset of less than 15 days that results in arm weakness right-handed 65-84 years of age manual muscle test score of at least 2/5 must be able to follow 2-3 step commands head, neck, and trunk control to maintain an upright posture for a minimum of 45 minutes some synergistic movement at shoulder active shoulder flexion and/or abduction greater then 30 degrees active elbow flexion of 45 degrees or more exclusion criteria * previous stroke history * hemorrhagic stroke, cerebellar stroke, or subarachnoid hemorrhage * contractures in the involved upper extremity at the shoulder, elbow, or wrist * moderate to severe tone in the involved upper extremity * flaccid involved upper extremity * full, active isolated movement of the involved upper extremity * corrected visual acuity worse than 20/50 for distance * cognitive or other deficits that would negatively affect their ability to follow directions or track visual targets * unstable cardiovascular orthopedic or neurological conditions that would preclude exercise in short-duration, high work-load trials

Keywords: stroke acute arm robot therapy arm paresis
pohca resuscitation: evaluation of im epinephrine

Conditions: Pediatric Out-of-Hospital Cardiac Arrest

Summary: this is a pragmatic, two-arm, open-label, prospective stepped-wedge cluster quasi randomized control trial (sw-crct) looking to evaluate early intramuscular (im) epinephrine in the management of pediatric out-of-hospital cardiac arrest (pohca).

im epinephrine may provide a more efficient means of administering the initial epinephrine dose (versus iv/io administration) to a child experiencing pediatric out of hospital cardiac arrest (pohca) with no greater risk of harm. in so doing, this may improve the short- and long-term outcomes of these patients. there is an abundance of literature detailing the risk/benefit profile of im epinephrine use in anaphylaxis; however, there is no human data on this topic as it relates to cardiac arrest. important knowledge gaps include whether the use of im epinephrine via autoinjector and/or pre-filled syringe leads to faster administration of the initial doses of epinephrine without delaying time to definitive epinephrine (via iv/io) and the impact on time to initial and sustained return of spontaneous circulation (rosc). this trial will be the first to examine the role of im epinephrine via autoinjector/pre-filled syringe in pohca.

Eligibility criteria:
inclusion criteria: * children aged 1 day to and including 17 years experiencing an out-of-hospital cardiac arrest (ohca) * must be receiving at least 1 minute of cpr by trained first responders (police, fire, or paramedic services) exclusion criteria: - children who experience ohca due to an obvious traumatic event.

Keywords: cardiac arrest im epinephrine standard of care pediatric resuscitation
treatment of atrophic acne scars with a fractional co2 laser at 1 versus 3 months intervals

Conditions: Atrophic Acne Scars

Summary: to compare efficacy and adverse effects of fractional co2 laser of acne scars treatment with 1 versus 3 months intervals

change in scar texture evaluated by blinded evalutaions. appearance of erythema, oedema, pigmentation, infection after treatment

Eligibility criteria:
inclusion criteria: * have fitzpatrick skin type i-iii. (•are male or female. * are between 18 and 60 years of age. * mild to severe acne scarring. * are able to read, understand, and sign the informed consent. * are willing and able to comply with all follow-up requirements - exclusion criteria: * have had active localized or systemic infections within 6 months of enrollment * have compromised ability for wound healing, such as: malnutrition, oral steroid use, history of collagen vascular disease (e.g. lupus, scleroderma, history of keloid formation (raised and thickened scars), atrophic dermatitis (extreme skin irritation or itchiness) or immunologic abnormalities such as vitiligo (white patches of skin due to loss of pigment) * have been treated with lasers, chemical procedures, or other cosmetic procedures on the area to be treated within 6 months of enrollment * pregnancy

Keywords: skin texture, efficacy, adverse effects
n-gal allows intensive treatment of contrast induced nephropathy

Conditions: Coronary Artery Disease

Summary: patients who undergo urgent/emergency coronary angiography can not receive any preventive treatment of contrast induced nephropathy. we tested the hypothesis that neutrophil gelatinase-associated lipocalin (ngal), a new biomarker predictive for aki, allows early and effective treatment of contrast induced nephropathy in patients with urgent/emergency coronary angiography

background patients who undergo urgent/emergency coronary angiography can not receive any preventive treatment of contrast induced nephropathy. an acute kidney injury is generally detected too late to allow effective intervention in patients who undergo urgent/emergency coronary angiography. neutrophil gelatinase-associated lipocalin (ngal) is a new biomarker predictive for aki already shown to be useful for earlier diagnosis of contrast induced nephropathy. purpose the primary objective of this study is to to test the hypothesis that a ngal-driven early intensive strategy can reduce the occurrence of contrast induced nephropathy in patients with urgent/emergency coronary angiography

Eligibility criteria:
inclusion criteria: * indication to urgent/emergency coronary angiography * normal renal function (egfr\> 60 ml/min/1.73 m2) * moderate or high mehran's risk score for cin (\>11). * able to understand and willing to sign the informed consent form exclusion criteria: • women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before

Keywords: contrast-induced nephropathy
power-speed-endurance profile (cycling/rowing) : optimize performance of the french athletes at the paris olympics 2024

Conditions: Healthy Volunteers; Performance

Summary: as part of the preparation at the paris 2024 olympic games, the french rowing and cycling federations and a consortium of researchers met to reach an ultimate goal: to increase the number of medals in these two disciplines for paris 2024 olympics.

the objective of this study is to evaluate the maximum capacity of power production of athletes by describing their power-endurance profile and the physiological factors underlying this maximum power generation capacity. these assessments will guide coaches and athletes for: 1. the best use of athletes' physical abilities (for race strategy, cycling gear ratio or rowing levers) 2. adaptation of training program to improve the maximum capacity of power production of the athletes, in order to increase the number of medals at the paris olympics 2024.

Eligibility criteria:
inclusion criteria: * experienced, well-trained (national to international level) rowers and cyclists * written consent exclusion criteria: * taking medications interfering with measured parameters * contraindication to competitive sport practice * currently participating in an other structured exercise program * muscular, bone or joint injuries * neurologic disease * pregnant

Keywords: biomechanics track cyclists and rowers energetics muscle fatigue